Claro Advisors LLC Cuts Stock Position in Cencora, Inc. (NYSE:COR)

Claro Advisors LLC decreased its holdings in shares of Cencora, Inc. (NYSE:COR) by 5.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,185 shares of the company’s stock after selling 66 shares during the period. Claro Advisors LLC’s holdings in Cencora were worth $266,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Concord Wealth Partners bought a new stake in shares of Cencora in the 3rd quarter valued at approximately $30,000. SYSTM Wealth Solutions LLC bought a new stake in Cencora in the second quarter worth $36,000. Ashton Thomas Securities LLC bought a new stake in Cencora in the third quarter worth $41,000. Fairscale Capital LLC purchased a new position in Cencora during the second quarter worth $54,000. Finally, Modus Advisors LLC bought a new position in Cencora during the fourth quarter valued at $54,000. Institutional investors own 97.52% of the company’s stock.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now directly owns 285,088 shares in the company, valued at approximately $67,223,750.40. This trade represents a 7.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 94,696 shares of company stock worth $22,862,734 in the last three months. Corporate insiders own 15.80% of the company’s stock.

Analyst Ratings Changes

COR has been the subject of several analyst reports. Wells Fargo & Company lowered their target price on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a report on Friday, December 13th. Bank of America reissued a “neutral” rating and issued a $245.00 price objective (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. UBS Group boosted their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Robert W. Baird increased their price target on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Finally, Evercore ISI boosted their price objective on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $275.60.

Cencora Trading Down 1.0 %

Shares of NYSE COR opened at $237.74 on Thursday. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $253.27. The firm has a market cap of $45.95 billion, a PE ratio of 31.66, a price-to-earnings-growth ratio of 1.54 and a beta of 0.49. The business has a fifty day simple moving average of $237.79 and a two-hundred day simple moving average of $233.67. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were paid a $0.55 dividend. The ex-dividend date was Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a yield of 0.93%. Cencora’s dividend payout ratio is 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.